Navigation Links
Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer,Patients Treated with Therapy Based on Ratiometric Dosing

Phase I results for CPX-1 presented at ASCO confirm safety findings and demonstrate clinical benefit in more than 70% of patients with colorectal and other types of cancer.

PRINCETON, N.J., June 04, 2007 /PRNewswire/ -- Celator Pharmaceuticals announced positive safety and efficacy results from its Phase I study of CPX-1 (Irinotecan HCI:Floxuridine), Liposome Injection in patients with heavily pre-treated, advanced solid tumors. Results were presented yesterday in a poster presentation at the American Society of Clinical Oncology (ASCO) meeting in Chicago.

Among a total of 33 patients with different types of cancer who were treated in the dose-escalating study, 73% showed clinical benefit including either partial regression or stable disease. In ten patients delay of disease progression was greater than six months. Among a subset of 15 patients with colorectal cancer, median duration of progression-free survival was 5.3 months. Of these patients, 80% received CPX-1 as a third, fourth or fifth line treatment, and 66% had prior treatment with irinotecan.

"These results provide us with the essential dosing and safety data we need to advance CPX-1 through Phase 2 clinical trials and toward commercialization. Even more importantly, this study also produced very encouraging results related to clinical benefit, which is uncommon in a Phase 1 study," said Andrew Janoff, Ph.D., CEO of Celator.

CPX-1 is a combination therapy including irinotecan HCI and floxuridine, two approved and well known drug agents to treat cancer. The formulation of CPX-1 was developed based on ratiometric dosing using Celator's CombiPlex(TM) technology platform, a proprietary technology that identifies the optimal ratio of drugs to use in combination therapies and then incorporates an advanced nanoparticle delivery system to maintain those optimal ratios when drugs are administered and metabolized in patients. Pending regula tory approval, CPX-1 would be the first commercially-available combination therapy based on Celator's ratiometric dosing drug development platform.

"What we found in this study is that our ratiometric dosing formulation of irinotecan and floxuridine achieved the targeted 1:1 molar ratio that provided synergistic benefits to all patients including those who had been treated previously with irinotecan. Based on these findings, Celator is moving forward with a Phase 2 study for CPX-1 that includes treatment of irinotecan- naïve patients as well as patients who are resistant or refractory to irinotecan," said Arthur Louie, M.D., Celator's chief medical officer.

The ongoing phase 2 study for CPX-1 involves patients with colorectal cancer who will be treated at sites in the U.S. and Canada. For information, visit: www.clinicaltrials.gov/ct/show/NCT00361842?order=1.

ABOUT CELATOR

Celator Pharmaceuticals, Inc., formerly Celator Technologies, Inc., is a privately held biopharmaceutical company working to develop new and more effective therapies to treat cancer. CombiPlex, the company's drug ratio technology platform, represents a revolutionary new approach to the development of combination therapies based on the optimal ratio of drug agents to target cancer cells effectively. The company pipeline includes: CPX-1, currently in Phase 2 trials as a treatment option for colorectal cancer; CPX-351, currently in Phase 1 trials as a treatment for leukemia (for information visit www.clinicaltrials.gov/ct/show/NCT00389428?order=2); CPX 571, now positioned to advance to Phase 1 trials and targeting small cell lung cancer; and multiple early stage pre-clinical development programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents.

CONTACT: Paul Hendley of Celator Pharmaceuticals, +1-212-253-8881, phendley@berrypr.com

Web site: http://www.clinicaltrials.gov/ct/show/NCT00361842?order=1/http://www.clinicaltrials.gov/ct/show/NCT00389428?order=2//

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... The Global Effective Microorganisms (EM) Market by Manufacturers, ... and analysed the potential of Global Effective Microorganisms (EM) Market ... growth factors. The report identifies and analyses the emerging trends ... market. ... and Figures, 6 Major Company Profiles, spread across 124 pages ...
(Date:4/19/2017)... LONDON , April 19, 2017 ... to stimulate an immune response in pets such ... vaccine products are of various types such as ... Vaccines, Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. ... such as virus or bacteria, which have been ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-naïve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
Breaking Medicine Technology:
(Date:4/26/2017)... Aviv, Israel (PRWEB) , ... April 26, 2017 , ... ... today announced a new partnership with Med-e-Mass , the largest Electronic Medical Records ... enable Med-e-Mass to link care plan incentives to a patient’s remote health progress, empowering ...
(Date:4/26/2017)... ... ... Miami native and local periodontist Dr. John Paul Gallardo is ... in 1991 that this journey would have taken me into so many learning experiences ... Gallardo has pioneered implant dentistry innovation, evolving into an internationally recognized leader in the ...
(Date:4/26/2017)... (PRWEB) , ... April 26, ... ... which provides an agile ecosystem and domain expertise for sponsors and CROs ... randomization and trial supply management (RTSM) software platform. Bioclinica AGILE RTSM ...
(Date:4/25/2017)... KY (PRWEB) , ... April 25, 2017 , ... ... announce they have signed an agreement to be the preferred physical therapy provider ... injuries and returning them to Derby City CrossFit as quickly and effectively as ...
(Date:4/25/2017)... ... April 25, 2017 , ... A recent report from ... performance for the 2015-16 school year across Wisconsin’s public schools, charter schools, and ... important patterns in student test score performance, the report’s limited analyses fail to ...
Breaking Medicine News(10 mins):